{"id":1009,"date":"2016-08-19T16:57:49","date_gmt":"2016-08-19T11:27:49","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1009"},"modified":"2021-07-24T12:56:31","modified_gmt":"2021-07-24T07:26:31","slug":"business-cocktail","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail","title":{"rendered":"Business Cocktail"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Zymeworks licenses new drug discovery platform from Innovative Targeting Solutions<br \/>\n<\/strong><strong>Zymeworks<\/strong>, a biotech company working on bispecific antibodies, has signed a licensing deal with <strong>Innovative Targeting Solutions (ITS)<\/strong> for <strong>HuTARG<\/strong>, which works as a protein engineering platform, and is the first fully mammalian tech that has the ability to generate antibody diversity <em>in vitro<\/em> via RAG1\/RAG2 mediated V(D)J recombination. The deal states that <strong>Zymeworks<\/strong> will pay an undisclosed amount for tech license fee to get hold of ITS\u2019s HuTARG drug discovery platform.<\/p>\n<p style=\"text-align: justify;\"><strong>NYU Langone Medical Center and Vedanta to codevelop microbiome-based cancer immunotherapies<br \/>\n<\/strong>A partnership between <strong>Vedanta Biosciences<\/strong> and <strong>NYU Langone Medical Center<\/strong> may lead to the development of <strong>microbiome-derived immunotherapies<\/strong> that might be specifically used to pair with checkpoint inhibitors. The main developmental goal is to use the microbiome to help improve the treatment of cancer, and also to increase the efficacy of this major developing class of oncology drugs.<\/p>\n<p style=\"text-align: justify;\"><strong>Partnership between California Life Sciences Association and OCTANe Announce to Bolster Orange County\u2019s Life Sciences Sector<br \/>\n<\/strong>USA\u2019s largest statewide public policy and business solutions organization representing California\u2019s leading life sciences innovators, and <strong>OCTANe<\/strong>, Orange County&#8217;s life sciences and technology accelerator organization, announced on August 17, 2016, an alliance to accelerate the growth of Orange County\u2019s life sciences sector.<\/p>\n<p style=\"text-align: justify;\"><strong>Pfenex gains back rights to Lucentis biosimilar from Pfizer<br \/>\nPfenex<\/strong> had partnered its biosimilar, PF582, with <strong>Hospira<\/strong>, under a collaboration in February 2015. Pfizer bought Hospira for <strong>$17bn<\/strong> last September. However, now Pfizer has pulled out of the biosimilar program, handing all the PF582 rights back to <strong>Pfenex<\/strong>. Pfizer has reconsidered developing <strong>Lucentis\u00a0(ranibizumab)<\/strong> biosimilar due to mounting competition, and has decided to end a development deal with <strong>Pfenex. Lucentis<\/strong> (ranibizumab) is marketed by Roche and Novartis. These companies reported that sales \u00a0of Lucentis were affected by its\u00a0competitor <strong>Eylea<\/strong> (aflibercept), which is a drug marketed by <strong>Regeneron<\/strong> and <strong>Bayer<\/strong>, whose sale figures in 2015 were up by 50% to hit $4.1 billion.<\/p>\n<p style=\"text-align: justify;\"><strong>A Reverse Merger Deal Leads Rasna Therapeutics to Become a Publicly Traded Company<br \/>\nRasna Therapeutics<\/strong>, a Leukemia and lymphoma biotech company, has pulled off a reverse merger, and the previously privately held company will list the OTC Markets under the symbol &#8220;<strong>ATVM<\/strong>.&#8221; The newly emerged public company works on cancer drugs and is currently developing molecular targets LSD1 and NPM1, targets implicated in the progression of leukemia and lymphoma.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zymeworks licenses new drug discovery platform from Innovative Targeting Solutions Zymeworks, a biotech company working on bispecific antibodies, has signed a licensing deal with Innovative Targeting Solutions (ITS) for HuTARG, which works as a protein engineering platform, and is the first fully mammalian tech that has the ability to generate antibody diversity in vitro via [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1040,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[631,17280,946,17279,17283,17281,17282,460,17284,2249,1634],"industry":[17225],"therapeutic_areas":[],"class_list":["post-1009","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biosimilar","tag-california-life-sciences-association","tag-hospira","tag-innovative-targeting-solutions","tag-lucentis-biosimilar","tag-octane","tag-pfenex","tag-pfizer","tag-rasna-therapeutics","tag-vedanta-biosciences","tag-zymeworks","industry-pharmaceutical"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Recent happenings in Zymeworks, Vedanta Biosciences, Pfizer<\/title>\n<meta name=\"description\" content=\"Zymeworks, a biotech company working on bispecific antibodies, has signed a licensing deal with Innovative Targeting Solutions (ITS) for HuTARG,\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recent happenings in Zymeworks, Vedanta Biosciences, Pfizer\" \/>\n<meta property=\"og:description\" content=\"Zymeworks, a biotech company working on bispecific antibodies, has signed a licensing deal with Innovative Targeting Solutions (ITS) for HuTARG,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-08-19T11:27:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"602\" \/>\n\t<meta property=\"og:image:height\" content=\"339\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Recent happenings in Zymeworks, Vedanta Biosciences, Pfizer","description":"Zymeworks, a biotech company working on bispecific antibodies, has signed a licensing deal with Innovative Targeting Solutions (ITS) for HuTARG,","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail","og_locale":"en_US","og_type":"article","og_title":"Recent happenings in Zymeworks, Vedanta Biosciences, Pfizer","og_description":"Zymeworks, a biotech company working on bispecific antibodies, has signed a licensing deal with Innovative Targeting Solutions (ITS) for HuTARG,","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-08-19T11:27:49+00:00","article_modified_time":"2021-07-24T07:26:31+00:00","og_image":[{"width":602,"height":339,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail","name":"Recent happenings in Zymeworks, Vedanta Biosciences, Pfizer","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","datePublished":"2016-08-19T11:27:49+00:00","dateModified":"2021-07-24T07:26:31+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Zymeworks, a biotech company working on bispecific antibodies, has signed a licensing deal with Innovative Targeting Solutions (ITS) for HuTARG,","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","width":602,"height":339},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biosimilar<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">California Life Sciences Association<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hospira<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Innovative Targeting Solutions<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lucentis Biosimilar<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">OCTANe<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfenex<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Rasna Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vedanta Biosciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zymeworks<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biosimilar<\/span>","<span class=\"advgb-post-tax-term\">California Life Sciences Association<\/span>","<span class=\"advgb-post-tax-term\">Hospira<\/span>","<span class=\"advgb-post-tax-term\">Innovative Targeting Solutions<\/span>","<span class=\"advgb-post-tax-term\">Lucentis Biosimilar<\/span>","<span class=\"advgb-post-tax-term\">OCTANe<\/span>","<span class=\"advgb-post-tax-term\">Pfenex<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Rasna Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Vedanta Biosciences<\/span>","<span class=\"advgb-post-tax-term\">Zymeworks<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 19, 2016","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 19, 2016 4:57 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1009"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1009\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1040"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1009"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1009"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}